Drugs for Thyroid Gland Papillary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 36)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Iodine |
Approved, Investigational |
Phase 2, Phase 3 |
|
7553-56-2 |
807
|
|
Synonyms:
diiodine
I2
Iode
Iodine-molecule
Iodio
iodo
|
Iodum
Jod
Jood
molecular iodine
Molecular iodine
Tincture iodine
|
|
| 2 |
|
Trace Elements |
|
Phase 2, Phase 3 |
|
|
|
| 3 |
|
Micronutrients |
|
Phase 2, Phase 3 |
|
|
|
| 4 |
|
Nutrients |
|
Phase 2, Phase 3 |
|
|
|
| 5 |
|
Anti-Infective Agents, Local |
|
Phase 2, Phase 3 |
|
|
|
| 6 |
|
Anti-Infective Agents |
|
Phase 2, Phase 3 |
|
|
|
| 7 |
|
cadexomer iodine |
|
Phase 2, Phase 3 |
|
|
|
| 8 |
|
Calcium carbonate |
Approved, Investigational |
Phase 2 |
|
471-34-1 |
|
|
Synonyms:
Calcio carbonato
Calcium carbonate (1:1)
Calciumcarbonat
Carbonate de calcium
Carbonato de calcio
|
Carbonic acid calcium salt (1:1)
Chalk
Kalziumkarbonat
Kohlensaurer kalk
Precipitated calcium carbonate
|
|
| 9 |
|
Bortezomib |
Approved, Investigational |
Phase 2 |
|
179324-69-7 |
93860
387447
|
|
Synonyms:
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
179324-69-7
341, PS
AC1L8TUW
bortezomib
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP 341
LDP341
LDP-341
|
LPD 341
LPD-341
MLN341
MolPort-003-845-298
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
NCI60_029010
NSC681239
NSC-681239
PROSCRIPT BORONIC ACID
PS 341
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
|
|
| 10 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
|
|
Synonyms:
|
| 11 |
|
Lenvatinib |
Approved, Investigational |
Phase 2 |
|
417716-92-8 |
|
|
Synonyms:
4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide
E7080
|
|
|
| 12 |
|
Sorafenib |
Approved, Investigational |
Phase 2 |
|
284461-73-0 |
216239
406563
|
|
Synonyms:
284461-73-0
4-(4-((((4-chloro-3-(Trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-chloro-3-Trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 439006
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY43-9006
BAY-43-9006
BAY-54-9085
Bio-0100
BRD-K23984367-001-01-8
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
D08524
|
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(Trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
nchembio.117-comp17
Nexavar
NSC-724772
NSC747971
sorafenib
Sorafenib
Sorafénib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib N-oxide
Sorafenib tosylate
sorafenibum
Sorafenibum
STK627350
UNII-9ZOQ3TZI87
ZINC01493878
|
|
| 13 |
|
Tyrosine |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
60-18-4 |
6057
|
|
Synonyms:
(-)-a-amino-P-Hydroxyhydrocinnamate
(-)-a-amino-P-Hydroxyhydrocinnamic acid
(-)-alpha-amino-P-Hydroxyhydrocinnamate
(-)-alpha-amino-P-Hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-α-amino-P-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-α-amino-P-hydroxyhydrocinnamic acid
(2S)-2-amino-3-(4-Hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-amino-3-(4-Hydroxyphenyl)propanoic acid
(S)-(-)-Tyrosine
(S)-2-Amino-3-(4-hydroxyphenyl)propionic acid
(S)-2-amino-3-(P-Hydroxyphenyl)propionate
(S)-2-amino-3-(P-Hydroxyphenyl)propionic acid
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-3-(P-Hydroxyphenyl)alanine
(S)-a-amino-4-Hydroxybenzenepropanoate
(S)-a-amino-4-Hydroxy-benzenepropanoate
(S)-a-amino-4-Hydroxybenzenepropanoic acid
(S)-a-amino-4-Hydroxy-benzenepropanoic acid
(S)-alpha-amino-4-Hydroxybenzenepropanoate
(S)-alpha-amino-4-Hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-amino-4-Hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoic acid
(S)-Tyrosine
(S)-α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
140-43-2
1991-85-1
25619-78-7
2-amino-3-(4-Hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-amino-3-(4-Hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionic acid
2csm
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
46209-14-7
4-hydroxy-L-phenylalanine
4-Hydroxy-L-phenylalanine
4ts1
55520-40-6
60-18-4
93829_FLUKA
93829_SIGMA
AB1002647
AC-11295
AC1L1LPI
AC1Q4U7L
AC1Q4U7M
AI3-09055
alpha-Amino-beta-(4-hydroxyphenyl)propionic acid
AR-1J3457
BB_NC-1194
Benzenepropanoate
Benzenepropanoic acid
beta-(p-Hydroxyphenyl)alanine
bmse000051
C00082
CHEBI:17895
CHEMBL925
CID6057
D00022
DB00135
|
DB03839
DD69927C-C6A8-4BC6-8E9A-0AB423B176E7
DTY
EINECS 200-460-4
FEMA No. 3736
Free-Form L-Tyrosine
HSDB 2003
H-Tyr-OH
L Tyrosine
L-(-)-Tyrosine
L-2-Amino-3-p-hydroxyphenylpropanoic acid
L-p-Tyrosine
L-P-Tyrosine
LS-2336
L-Tyrosin
L-tyrosine
L-Tyrosine (9CI)
L-Tyrosine (JAN)
L-Tyrosine hydrochloride
L-Tyrosine, homopolymer
L-Tyrosine, monomer
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction
Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide
Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours
MolPort-001-792-016
NCGC00159350-02
NCGC00159350-03
nchembio.105-comp1
nchembio.121-comp7
nchembio.186-comp84
nchembio.284-comp7
nchembio816-comp11
NSC 82624
Para tyrosine
Para-tyrosine
p-Tyrosine
P-Tyrosine
Rxosine
T0550
T3754_SIAL
T4321_SIAL
T4321_SIGMA
T8566_SIGMA
tirosina
Tirosina
Tirosina [Spanish]
tyr
Tyr
TYR NH3+ COOH
tyrosine
Tyrosine
TYROSINE
Tyrosine (USP/INN)
Tyrosine (VAN)
Tyrosine [USAN:INN]
Tyrosine Power
Tyrosine, L- (8CI)
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Tyrosinum [Latin]
UNII-42HK56048U
W373605_ALDRICH
Y
|
|
| 14 |
|
Alfacalcidol |
Approved, Nutraceutical |
Phase 2 |
|
41294-56-8 |
5282181
|
|
Synonyms:
(5Z,7E)-9,10-seco-5,7,10(19)-Cholestatrien-1a,3b-diol
(5Z,7E)-9,10-seco-5,7,10(19)-Cholestatrien-1alpha,3beta-diol
(5Z,7E)-9,10-seco-5,7,10(19)-cholestatrien-1α,3β-diol
(5Z,7E)-9,10-seco-5,7,10(19)-Cholestatrien-1α,3β-diol
1 alpha-Hydroxycholecalciferol
1 alpha-Hydroxyvitamin D3
1a-Hydroxycholecalciferol
1a-Hydroxyvitamin D3
1a-Hydroxy-vitamin D3
1alpha-hydroxycholecalciferol
1alpha-Hydroxycholecalciferol
1alpha-Hydroxyvitamin D3
1alpha-Hydroxy-vitamin D3
1alpha-OHD3
1-alpha-Oxycholecalciferol
1-hydroxycholecalciferol
1-Hydroxycholecalciferol
1-Hydroxycholecalciferol, (1alpha,3alpha-(5Z,7E))-isomer
1-Hydroxycholecalciferol, (1beta)-(5Z)-isomer
1-Hydroxycholecalciferol, (1beta,3beta-(5E,7E))-isomer
1-Hydroxycholecalciferol, aluminum salt
|
1α-hydroxycholecalciferol
1α-hydroxyvitamin D3
1α-hydroxy-vitamin D3
9,10-Secocholesta-5,7,10(19)-triene-1a,3b-diol
9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta-diol
9,10-secocholesta-5,7,10(19)-triene-1α,3β-diol
9,10-Secocholesta-5,7,10(19)-triene-1α,3β-diol
Alfacalcidol
Alfacalcidolum
AlfaD
Alphacalcidol
Alsiodol
Bondiol
Doss brand OF alfacalcidol
Eenalfadrie
EinsAlpha
Etalpha
Oksidevit
One-Alpha
Un-alfa
|
|
| 15 |
|
Ergocalciferol |
Approved, Nutraceutical |
Phase 2 |
|
50-14-6 |
5280793
|
|
Synonyms:
(+)-Vitamin D2
(3b,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-Ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,secoergosta-5,7,10(19)-ol
31316-19-5
47768_SUPELCO
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3ah)-indanylidene]ethylidene]-cyclohexanol
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
beta-Ol
bmse000510
BPBio1_000418
BSPBio_000380
BSPBio_001974
buco-D
Buco-D
C05441
C28H44O
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
Calciferols
Calciferolum
Calciferon 2
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
component of Geltabs Vitamin D
Condacaps
Condocaps
Condol
Crtron
Crystallina
D00187
D2, Vitamin
Daral
D-Arthin
Davitamon D
Davitin
DB00153
Decaps
Dee-osterol
Dee-Osterol
Dee-ron
Dee-Ron
Dee-ronal
Dee-Ronal
Dee-roual
Dee-Roual
delta-Arthin
Deltalin
delta-Tracetten
De-rat concentrate
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
D-Tracetten
E5750_SIGMA
EINECS 200-014-9
Ercalciol
ergocalciferol
|
Ergocalciferol
Ergocalciférol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
'Ergosterol irradiated'
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
Haliver
Hi-deratol
Hi-Deratol
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
Metadee
Mina D2
MLS001332467
MLS001332468
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
Novovitamin-D
NSC 62792
NSC62792
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick_554
Prestwick3_000420
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
Shock-ferol
Shock-ferol sterogyl
SMR000857106
Sorex C.R
Sorex C.R.
SPECTRUM1500276
Spectrum5_000666
ST057150
Sterogyl
STOCK1N-53397
Synthetic vitamin D
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
Vigantol
vio D
vio-D
Vio-D
Viostdrol
Viosterol
Viosterol in oil
Viosterol in Oil
Vitamin D 2
vitamin d-2
Vitamin D2
Vitamin- D2
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
Vitamin-?D2
VITAMIN_D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
|
|
| 16 |
|
Vitamin D |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
1406-16-2 |
|
|
Synonyms:
|
|
Vitamin D, unspecified form
|
|
| 17 |
|
Calcium |
Approved, Nutraceutical |
Phase 2 |
|
7440-70-2 |
271
|
|
Synonyms:
Blood coagulation factor XIII
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
CALCIUM ion
Calcium, doubly charged positive ion
Calcium, elemental
Coagulation factor XIII
Elemental calcium
Factor XIII
|
Factor XIII a chain
Factor XIII a-chain
Factor XIII transamidase
Factor XIII, coagulation
Fibrin stabilizing factor
Fibrinase
Kalzium
Laki lorand factor
Laki-lorand factor
Stabilizing factor, fibrin
Transamidase, factor XIII
XIII, coagulation factor
|
|
| 18 |
|
Liver Extracts |
|
Phase 2 |
|
|
|
| 19 |
|
Antacids |
|
Phase 2 |
|
|
|
| 20 |
|
Hormones |
|
Phase 2 |
|
|
|
| 21 |
|
Vitamin D2 |
|
Phase 2 |
|
|
|
| 22 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
| 23 |
|
Vitamins |
|
Phase 2 |
|
|
|
| 24 |
|
Ergocalciferols |
|
Phase 2 |
|
|
|
| 25 |
|
Hydroxycholecalciferols |
|
Phase 2 |
|
|
|
| 26 |
|
Calciferol |
|
Phase 2 |
|
|
|
| 27 |
|
Calcium, Dietary |
|
Phase 2 |
|
|
|
| 28 |
|
Anti-Ulcer Agents |
|
Phase 2 |
|
|
|
| 29 |
|
Bone Density Conservation Agents |
|
Phase 2 |
|
|
|
| 30 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
| 31 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
| 32 |
|
Fluorodeoxyglucose F18 |
|
Phase 2 |
|
|
|
| 33 |
|
Radiopharmaceuticals |
|
Phase 2 |
|
|
|
| 34 |
|
Dabrafenib |
Approved, Investigational |
Phase 1 |
|
1195765-45-7 |
44462760
44516822
|
|
Synonyms:
BRAF inhibitor GSK2118436
dabrafenib
Dabrafenib
|
|
|
| 35 |
|
Anti-Inflammatory Agents |
|
|
|
|
|
| 36 |
|
Anesthetics |
|
|
|
|
|
Interventional clinical trials:
(show all 42)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial |
Completed |
NCT00795782
|
Phase 3 |
|
| 2 |
Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study |
Completed |
NCT01137097
|
Phase 2, Phase 3 |
|
| 3 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy |
Recruiting |
NCT03690388
|
Phase 3 |
Cabozantinib;Placebo |
| 4 |
Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients |
Recruiting |
NCT01398085
|
Phase 2, Phase 3 |
|
| 5 |
ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer |
Not yet recruiting |
NCT03570021
|
Phase 3 |
|
| 6 |
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma |
Completed |
NCT01502410
|
Phase 2 |
sorafenib tosylate |
| 7 |
Phase 2 Study of Routine Oral Calcium and Vitamine D Supplements to Prevent Hypocalcemia After Total Thyroidectomy in Papillary Thyroid Carcinoma Patients |
Completed |
NCT00630214
|
Phase 2 |
|
| 8 |
Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements |
Completed |
NCT00559949
|
Phase 2 |
Selumetinib |
| 9 |
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma |
Completed |
NCT00104871
|
Phase 2 |
Bortezomib |
| 10 |
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy |
Completed |
NCT01811212
|
Phase 2 |
Cabozantinib S-malate |
| 11 |
A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma |
Completed |
NCT01813136
|
Phase 2 |
Continuous pazopanib (Arm A);Intermittent pazopanib (Arm B) |
| 12 |
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study |
Recruiting |
NCT02973997
|
Phase 2 |
Lenvatinib |
| 13 |
Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma |
Terminated |
NCT00095693
|
Phase 2 |
sorafenib tosylate |
| 14 |
Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects With Advanced BRAF V600-Mutation Positive Solid Tumors |
Active, not recruiting |
NCT01677741
|
Phase 1 |
Dabrafenib |
| 15 |
Differences Protein Expression in Papillary Thyroid Carcinoma |
Unknown status |
NCT02814032
|
|
|
| 16 |
Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma |
Unknown status |
NCT01417442
|
Early Phase 1 |
|
| 17 |
99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study |
Unknown status |
NCT00984191
|
|
|
| 18 |
Clinical Investigations on Cytokin-Gradients in Hypo/Euthyroid Patients. Evaluation of Expression of Different Pro-and Anti-Inflammatory Cyto-/Chemokines in Skin Wounds After Surgery of Benign Goitres (Struma Multinodosa) or Malignant Diseases of Thyroid Gland (Papillary Thyroid Carcinoma) in Correlation to the Status of Wound Healing of the Neck Wound |
Unknown status |
NCT00929318
|
|
|
| 19 |
Does Robotic Assistance Significantly Reduce Postoperative Distress and Patient Complaints About Cosmetic Outcomes After Thyroid Surgery? A Preliminary Report. |
Unknown status |
NCT01075269
|
|
|
| 20 |
Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial |
Unknown status |
NCT02140476
|
|
|
| 21 |
The Effectiveness of Prophylactic Selective Lateral Neck Dissection in Papillary Thyroid Carcinoma Patients With Central Neck Metastasis |
Completed |
NCT01103557
|
|
|
| 22 |
Prognostic Significance of Fine-Needle Aspiration Cytology Features in Papillary Thyroid Carcinoma |
Completed |
NCT00459459
|
|
|
| 23 |
Immunohistochemical Detection of the BRAFV600E Mutation on Cytological Specimen in PTC |
Completed |
NCT02561533
|
|
|
| 24 |
Assessment of Serum Leptin Levels in Females With Papillary Thyroid Carcinoma, Benign Thyroid Nodules, and Normal Controls |
Completed |
NCT01659385
|
|
|
| 25 |
Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy |
Completed |
NCT01354639
|
|
|
| 26 |
APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS. |
Completed |
NCT02323724
|
|
|
| 27 |
A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy : Postoperative Body Image Change and Cosmetic Satisfaction |
Completed |
NCT01311089
|
|
|
| 28 |
Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 |
Completed |
NCT01534897
|
|
GSK2118436 |
| 29 |
Sentinel Node Investigation in Patients With Highly Differentiated Papillary Thyroid Carcinoma and in Patients With Thyroid Neoplasia of Unclear Malignant Potential |
Completed |
NCT01089335
|
|
|
| 30 |
Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy |
Completed |
NCT02347683
|
|
|
| 31 |
Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma? |
Completed |
NCT00439127
|
|
|
| 32 |
The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma |
Recruiting |
NCT02418390
|
|
|
| 33 |
A Strategy to Search for Genes Predisposing to Papillary Carcinoma of the Thyroid When Mutated |
Recruiting |
NCT02776969
|
|
|
| 34 |
Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma |
Recruiting |
NCT03889769
|
|
|
| 35 |
From the Endoscope to the Robot, the Initial Experience of Robotic Thyroidectomy is Summarized |
Recruiting |
NCT03454477
|
|
|
| 36 |
Active Surveillance of Papillary Thyroid Microcarcinoma |
Recruiting |
NCT02609685
|
|
|
| 37 |
Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules |
Recruiting |
NCT03309631
|
|
|
| 38 |
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging in Detecting Metastatic Central Lymph Nodes in Patients With Papillary Thyroid Cancer |
Recruiting |
NCT03830242
|
|
|
| 39 |
Prospective Study for the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma |
Not yet recruiting |
NCT03813706
|
|
|
| 40 |
Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma: a Prospective Study |
Not yet recruiting |
NCT03813173
|
|
|
| 41 |
A Prospective Randomized Trial Comparing Ultrasound-guided High Intensity Focused Ultrasound (HIFU) Ablation With Active Surveillance (AS) in the Management of Low-risk Papillary Thyroid Microcarcinoma (PTMC) |
Suspended |
NCT03327636
|
|
|
| 42 |
Central Compartment Neck Dissection Total Thyroidectomy: a Randomized Controlled Trial |
Terminated |
NCT01106443
|
|
|
|
